Oral MIB-626 (β Nicotinamide Mononucleotide) Safely Raises Blood Nicotinamide Adenine Dinucleotide Levels in Hospitalized Patients With COVID-19 and Acute Kidney Injury: A Randomized Controlled Trial.

Pencina KM, Leaf DE, Valderrabano RJ, Waikar SS, Mehta TS, Shang YV, Latham NK, John T, Volpi E, Fusco D, Memish-Beleva Y, Krishnamurthy S and 4 more

Show all authors

Lavu S, Karmi S, Livingston DJ, Bhasin S

FASEB bioAdvances18 Jun 2025Cited by 1 (Europe PMC)

PMID40746868PMCIDPMC12312518DOI10.1096/fba.2025-00014PepBankPUB-40746868

Read at source PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In hospitalized adults with COVID-19 and AKI, serum creatinine changes did not differ between MIB-626 and placebo.
In plain wordsIn hospitalized adults with COVID-19 and kidney injury, creatinine changes did not differ between MIB-626 and placebo.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
No significant changeSerum creatinine
Study
n = 42
Comparator
placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
1.0 g twice daily · oral · 14 daysAs given in this study (human).
Source sentences
Summary
Changes in serum creatinine, cystatin-C, and serum markers of AKI did not differ significantly between groups.
1 context sentence(design, population, supporting numbers)
Summary · context
42 adults, ≥ 18 years, hospitalized with COVID-19 and AKI, were randomized in a 3:2 ratio to MIB-626 1.0-g or placebo tablets twice daily for 14 days.
Report a problemFND-4074686804
02HumanRandomized controlled trialEfficacy outcome
In hospitalized adults with COVID-19 and AKI, cystatin-C changes did not differ between MIB-626 and placebo.
In plain wordsIn hospitalized adults with COVID-19 and kidney injury, cystatin-C changes did not differ between MIB-626 and placebo.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
No significant changeSerum cystatin-C
Study
n = 42
Comparator
placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
1.0 g twice daily · oral · 14 daysAs given in this study (human).
Source sentences
Summary
Changes in serum creatinine, cystatin-C, and serum markers of AKI did not differ significantly between groups.
1 context sentence(design, population, supporting numbers)
Summary · context
42 adults, ≥ 18 years, hospitalized with COVID-19 and AKI, were randomized in a 3:2 ratio to MIB-626 1.0-g or placebo tablets twice daily for 14 days.
Report a problemFND-4074686805
03HumanRandomized controlled trialEfficacy outcome
In hospitalized adults with COVID-19 and AKI, serum AKI marker changes did not differ between MIB-626 and placebo.
In plain wordsIn hospitalized adults with COVID-19 and kidney injury, kidney injury marker changes did not differ between MIB-626 and placebo.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
No significant changeSerum AKI markers
Study
n = 42
Comparator
placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
1.0 g twice daily · oral · 14 daysAs given in this study (human).
Source sentences
Summary
Changes in serum creatinine, cystatin-C, and serum markers of AKI did not differ significantly between groups.
1 context sentence(design, population, supporting numbers)
Summary · context
42 adults, ≥ 18 years, hospitalized with COVID-19 and AKI, were randomized in a 3:2 ratio to MIB-626 1.0-g or placebo tablets twice daily for 14 days.
Report a problemFND-4074686806
04HumanRandomized controlled trialEfficacy outcome
In hospitalized adults with COVID-19 and AKI, serum CRP did not differ between MIB-626 and placebo.
In plain wordsIn hospitalized adults with COVID-19 and kidney injury, blood CRP did not differ between MIB-626 and placebo.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
No significant changeSerum CRP
Study
n = 42
Comparator
placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
1.0 g twice daily · oral · 14 daysAs given in this study (human).
Source sentences
Summary
Serum CRP, IL-6, and TNFα and indices of disease severity also did not differ between groups.
1 context sentence(design, population, supporting numbers)
Summary · context
42 adults, ≥ 18 years, hospitalized with COVID-19 and AKI, were randomized in a 3:2 ratio to MIB-626 1.0-g or placebo tablets twice daily for 14 days.
Report a problemFND-4074686807
05HumanRandomized controlled trialEfficacy outcome
In hospitalized adults with COVID-19 and AKI, serum IL-6 did not differ between MIB-626 and placebo.
In plain wordsIn hospitalized adults with COVID-19 and kidney injury, blood IL-6 did not differ between MIB-626 and placebo.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
No significant changeSerum IL-6
Study
n = 42
Comparator
placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
1.0 g twice daily · oral · 14 daysAs given in this study (human).
Source sentences
Summary
Serum CRP, IL-6, and TNFα and indices of disease severity also did not differ between groups.
1 context sentence(design, population, supporting numbers)
Summary · context
42 adults, ≥ 18 years, hospitalized with COVID-19 and AKI, were randomized in a 3:2 ratio to MIB-626 1.0-g or placebo tablets twice daily for 14 days.
Report a problemFND-4074686808
06HumanRandomized controlled trialEfficacy outcome
In hospitalized adults with COVID-19 and AKI, serum TNFα did not differ between MIB-626 and placebo.
In plain wordsIn hospitalized adults with COVID-19 and kidney injury, blood TNFα did not differ between MIB-626 and placebo.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
No significant changeSerum TNFalpha
Study
n = 42
Comparator
placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
1.0 g twice daily · oral · 14 daysAs given in this study (human).
Source sentences
Summary
Serum CRP, IL-6, and TNFα and indices of disease severity also did not differ between groups.
1 context sentence(design, population, supporting numbers)
Summary · context
42 adults, ≥ 18 years, hospitalized with COVID-19 and AKI, were randomized in a 3:2 ratio to MIB-626 1.0-g or placebo tablets twice daily for 14 days.
Report a problemFND-4074686809
07HumanRandomized controlled trialEfficacy outcome
In hospitalized adults with COVID-19 and AKI, disease severity indices did not differ between MIB-626 and placebo.
In plain wordsIn hospitalized adults with COVID-19 and kidney injury, disease severity did not differ between MIB-626 and placebo.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
No significant changeDisease severity indices
Study
n = 42
Comparator
placebo
Outcome group
Intensive care and hospital outcomes · Whole body
Studied dose
1.0 g twice daily · oral · 14 daysAs given in this study (human).
Source sentences
Summary
Serum CRP, IL-6, and TNFα and indices of disease severity also did not differ between groups.
1 context sentence(design, population, supporting numbers)
Summary · context
42 adults, ≥ 18 years, hospitalized with COVID-19 and AKI, were randomized in a 3:2 ratio to MIB-626 1.0-g or placebo tablets twice daily for 14 days.
Report a problemFND-4074686810
08HumanRandomized controlled trialPharmacokinetics
In hospitalized adults with COVID-19 and AKI, MIB-626 gradually increased blood NAD+ levels, peaking between days 5 and 14.
In plain wordsIn hospitalized adults with COVID-19 and kidney injury, MIB-626 increased blood NAD+ from baseline.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseBlood NAD+ levels
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
1.0 g twice daily · oral · 14 daysAs given in this study (human).
Measurements
Blood NAD+
16 μg/mL
baseline
Blood NAD+
25.5 μg/mL
day 5
Blood NAD+
42.6 μg/mL
day 14
Source sentences
Summary
MIB-626 treatment significantly but gradually raised blood NAD⁺ levels to a peak between 5 to 14 days (16.0 ± 6.9, 25.5 ± 12.6, and 42.6 ± 25.6 μg/mL at baseline, days 5 and 14)
1 context sentence(design, population, supporting numbers)
Summary · context
42 adults, ≥ 18 years, hospitalized with COVID-19 and AKI, were randomized in a 3:2 ratio to MIB-626 1.0-g or placebo tablets twice daily for 14 days.
Report a problemFND-4074686801
09HumanRandomized controlled trialPharmacokinetics
In hospitalized adults with COVID-19 and AKI, MIB-626 raised plasma concentrations of NAD+ metabolites, including 1-methylnicotinamide, to a peak by day 3.
In plain wordsIn hospitalized adults with COVID-19 and kidney injury, MIB-626 raised blood levels of NAD+ metabolites, peaking by day 3.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreasePlasma NAD+ metabolites
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
1.0 g twice daily · oral · 14 daysAs given in this study (human).
Source sentences
Summary
and raised plasma concentrations of NAD⁺ metabolites 1-methylnicotinamide, N-methyl, 2-pyridone, 4-carboxamide rapidly to a peak by day 3.
1 context sentence(design, population, supporting numbers)
Summary · context
42 adults, ≥ 18 years, hospitalized with COVID-19 and AKI, were randomized in a 3:2 ratio to MIB-626 1.0-g or placebo tablets twice daily for 14 days.
Report a problemFND-4074686802

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.